Kineta Inc. (KA)
0.57
-0.26 (-31.33%)
At close: Sep 18, 2024, 8:00 PM
0.60
4.33%
After-hours: Sep 18, 2024, 07:13 PM EDT
-31.33% (1D)
| Bid | n/a |
| Market Cap | 7.05M |
| Revenue (ttm) | -4.34M |
| Net Income (ttm) | -20.88M |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | -0.35036585365853656 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 480,683 |
| Avg. Volume (20D) | 504,100 |
| Open | 0.78 |
| Previous Close | 0.83 |
| Day's Range | 0.56 - 0.82 |
| 52-Week Range | 0.33 - 5.39 |
| Beta | 0.57 |
About KA
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington....
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2016
Employees 11
Stock Exchange NASDAQ
Ticker Symbol KA
Website https://kinetabio.com
8 months ago
+13.26%
Kineta shares are trading higher after the company...
Unlock content with
Pro Subscription
9 months ago
+8.77%
Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.